QUANTUM BIOPHARMA-B SUB VOT (QNTM) Stock News

USA - Nasdaq - NASDAQ:QNTM - CA74764Y2050 - Common Stock

8.57 USD

-1.13 (-11.65%)

Last: 12/1/2025, 5:42:02 PM

8.29 USD

-0.28 (-3.27%)

After Hours: 12/1/2025, 5:42:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

QNTM Latest News, Press Relases and Analysis

All

Press Releases

12 hours ago - By: Quantum BioPharma - Mentions: -

Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC

3 days ago - By: Quantum BioPharma

REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

3 days ago - By: Quantum BioPharma - Mentions: -

REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

6 days ago - By: Stocktwits

News Image

Quantum BioPharma Stock Rockets As Media Probe Shines Light On Spoofing Allegations Linked To Its $700M Lawsuit

2 months ago - By: ACCESS Newswire - Mentions: MDCX COEP

Three Biotech Companies Redefining Value Creation Through Dual Strategies

2 months ago - By: ACCESS Newswire

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

4 days ago - By: Quantum BioPharma

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

4 days ago - By: Quantum BioPharma - Mentions: -

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

5 days ago - By: Quantum BioPharma

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

5 days ago - By: Quantum BioPharma - Mentions: -

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

6 days ago - By: Quantum BioPharma

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

6 days ago - By: Quantum BioPharma - Mentions: -

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

24 days ago - By: Quantum BioPharma

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

24 days ago - By: Quantum BioPharma - Mentions: -

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

a month ago - By: Quantum BioPharma

Quantum BioPharma Ltd. Provides Corporate Update

a month ago - By: Quantum BioPharma

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

a month ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

a month ago - By: Quantum BioPharma

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

a month ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

2 months ago - By: Business Wire

KILL QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

2 months ago - By: Business Wire

KILL Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

2 months ago - By: Quantum BioPharma

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

2 months ago - By: Quantum BioPharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

2 months ago - By: Quantum BioPharma

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

2 months ago - By: Quantum BioPharma

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

2 months ago - By: Quantum BioPharma

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

2 months ago - By: Quantum BioPharma

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

2 months ago - By: Quantum BioPharma

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

2 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

2 months ago - By: Quantum BioPharma

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

2 months ago - By: Quantum BioPharma - Mentions: -

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

3 months ago - By: Quantum BioPharma

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

3 months ago - By: Quantum BioPharma - Mentions: -

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

3 months ago - By: Quantum BioPharma

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target